Ofev®

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyIdiopathic Pulmonary FibrosisInterstitial Lung DiseasesSystemic Sclerosis Associated Interstitial Lung Disease

Phase 1

A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib

CompletedNCT05262751

Boehringer IngelheimHealthy

Start: 2022-03-28End: 2022-11-30Updated: 2024-05-29

Unknown Phase

NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib

CompletedNCT04614441

Boehringer IngelheimIdiopathic Pulmonary Fibrosis

Start: 2021-01-21End: 2025-05-14Updated: 2025-08-19

A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis

Active, not recruitingNCT07080125

Boehringer IngelheimInterstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease

Start: 2025-06-17End: 2033-12-31Target: 2000Updated: 2025-12-08